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Abstract 
 
Excepting the Peripheral and Central Nervous Systems, the Immune System is the 
most complex of somatic systems in higher animals. This complexity manifests itself at 
many levels from the molecular to that of the whole organism. Much insight into this 
confounding complexity can be gained through computational simulation. Such 
simulations range in application from epitope prediction through to the modeling of 
vaccination strategies. In this review, we evaluate selectively various key applications 
relevant to computational vaccinology: these include technique that operates at 
different scale i.e., from molecular to organisms and even to population level.  
 
Keywords: vaccine research; modelling; computational vaccinology; immune 
system; epitopes; simulations. 
Introduction 
Despite its overwhelming and often confounding complexity, the immune system is 
ultimately a collection of parts working together to effect defence against pathogens 
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and many other homeostatic functions. The problem, of course, when one tries to 
understand the immune system, is the remarkable level of emergent behaviour we 
observe - at many levels - from the formation of supramolecular complexes at the 
Immune synapse; through the action of specific immune cells, such as dendritic cells 
and T-cells; to organs; and, finally, whole organisms. Beyond even the whole animal, 
effects such as herd immunity and infectivity patterns manifest themselves only in 
large, interacting pseudo-social networks. As we see, or allude to, elsewhere, much of 
this can be modelled, and modelled with some success. Yet despite the daunting 
emergent, higher-level behaviour we see, much can still be learned from attempting to 
understand and model the underlying molecular components that comprise the 
immune system. 
Nowadays biological systems are analysed and managed by means of new 
emerging technologies that are revolutionizing biotechnology and information 
technology, producing a huge amounts of data. This data needs to be integrated and is 
quickening the process of knowledge discovery, enabling the study of biological 
systems at various levels i.e., from molecules to organisms and even to the population 
level.  
The human activity entailing the representation, the manipulation and the 
communication of real-world daily life objects is known as modelling. Mathematical and 
computational models are gradually used to assist deduce biomedical data produced 
by high-throughput genomics and proteomics endeavours. The application of advanced 
computer models allowing the simulation of complex biological processes produces 
hypotheses and proposes experiments. Computational models are set to exploit the 
wealth of data stored on biomedical databases through text mining and knowledge 
discovery methods. 
The first immunoinformatics tools for vaccine design were developed in the 1980s 
by DeLisi and Berzofsky and others [56]. Chief among vaccine design informatics tools 
are epitope-mapping algorithms. A new era of vaccine research began in 1995, when 
the complete genome of Haemophilus influenzae (a pathogenic bacterium) was 
published [58]. In parallel with advances in molecular biology and sequencing 
technology, bioinformatics analysis of microbial genome data has allowed in silico 
selection of vaccine targets. Further advances in the field of immunoinformatics have 
led to the development of hundreds of new vaccine design algorithms. This novel 
approach for developing vaccines has been named reverse vaccinology [59] or 
immunome-derived vaccine design [60]. Pharmaceutical companies are starting to use 
 3 
models to optimize/predict therapeutic effects at the organism level, suggesting that 
computational biology can effectively play a key role in this field [57]. 
Along with these techniques, the simulation of the immune system in a detailed way 
to reproduce and predict the effects of artificial immunity elicited by vaccines 
represents a challenge that several people are attempting with success. The immune 
system represents one of the most complex biological system. It is, in fact, an adaptive 
learning system which operates at multiple levels (molecules, cells, organs, organisms, 
and groups of organisms). Immunological research, both basic and applied, needs to 
deal with this complexity [4]. 
In this paper, we analyse and discuss several computational modelling techniques 
applied to vaccinology science. 
Epitopes 
Arguably, the simplest unambiguous component of the immune is the so-called 
epitope. The epitope at its most generally defined is very much the immunological 
quantum that lies central to immune responses and vaccination. It is the ability of the 
immune system to identify, respond to, and remember epitopes that powers natural 
immunity, and thus vaccination. Peptide epitopes are mediated primarily by their 
interaction with Major Histocompatibility Complexes (T-cell Epitopes, or TCEs) and 
antibodies (B-cell epitopes, or BCE).  
Currently, commonly-used prediction of B cell epitopes often remains primitive, or 
depends on an elusive knowledge of protein structure, and both structure- [9] and data-
driven [10] prediction of antibody-mediated epitopes have again been shown to be 
poor. Explaining such sub-optimality may point to a fundamental misinterpretation of 
extant epitope data. PEPSCAN is perhaps the most abundant data available currently 
but may not be what it seems. Experimentally derived epitopes are identified by 
assayed against pre-existing antibodies with affinity for whole antigens. If, for example, 
“epitopes” are mapped back to their original antigen structure, we find them randomly 
located through the structure rather than equating to obvious surface patches, as might 
be expected if they simply reproduced discontinuous epitopes identified by 
crystallography.  In situ antigenic regions are often not exposed and thus accessible to 
binding by antibodies binding but rather completely buried. If we compare the 
conformation of antibody-bound peptides with those from the intact antigen, they are 
usually quite different. However, B-cell epitopes in isolated antigen and in whole 
antigen-antibody complexes are much more similar. Is it possible then, that the isolated 
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peptide adopts a conformation which mimics the surface features of a discontinuous 
epitope or that the preformed antibody recognize denatured antigen in vivo.  
Currently, prediction of T cell epitopes remains largely confined to predictions of 
varying accuracy of peptide binding to Major Histocompatibility Complex. Nonetheless, 
and compared to B-cell prediction, methods for predicting T cell epitopes show 
significant algorithmic sophistication. Prediction of the binding of peptides to class I 
MHCs, at least for well-studied alleles, such as HLA-A*0201, is now at useable 
accuracy [11]. However, comparative studies have shown recently that the prediction 
of class II MHC binding prediction T-cell epitopes is typically poor [12][13][14][15], and 
likewise for structure-driven prediction of class I and class II T-cell epitopes [16].  
All epitope prediction methods remain severely constrained by the data used to 
construct them; this is particularly true of T-cell prediction. It has recently been shown 
that that T-cell epitopes, which were previously thought to be short peptides of 8-10 
amino acids, can be up to 16 amino acids or perhaps even more. The existence of 
such longmer epitopes has significantly enlarged the repertoire of peptides open to 
inspection by T-cells [17]. Many of the cutting edge approaches to epitope discovery 
are trying to address these issues by inducing models of large numbers of alleles 
across many peptide lengths by making assumptions about how separable are the 
sub-sites in the peptide binding groove and how thee can be combined combinatorially 
to generate pseudo-binding profiles [18][19][20].  However, as is well-known, no data-
driven method can go beyond the data used to train it; all methods are likewise much 
superior in their ability to interpolate than their ability to extrapolate. 
Evidence exists that the responsiveness of the immune system to pathogenic 
proteins is only poorly correlated with the possession of T cell epitopes, and that many 
potential epitopes have been deleted in proteins regularly accessible to immune 
surveillance, perhaps as an evolutionary counter measure in the war between host and 
pathogen [21]. Such a deficit, and the significantly sub-optimal prediction of both B-cell 
and T-cell epitopes described above have suggested that methods which rely solely on 
the possession of epitopes are unlikely to be effective at identifying antigens or 
immunogens. This conjecture is confirmed by what information there is, which indicates 
that there is little simple correspondence between antigens selected on this basis and 
experimentally verified antigenic or protective proteins. In turn this has led to the 
development of other approaches to predicting whole antigens within pathogen 
genomes, proteins likely to be antigenic and protective; of which there are three key 
approaches: subcellular location prediction, sequence similarity, and empirical 
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statistical approaches, typified by VaxiJen [22][23] and expert systems such as nerve 
[24]. 
PAMPS and Adjuvants 
Other epitopes exist, notable the so-called Pathogen-Associated Molecular Pattern 
(or PAMP), highly conserved and typically complex molecular moieties recognised by 
pattern recognition receptors (or PRRs) of the innate immune system [25]. Many 
PAMPs, and molecules mimicking the recognition of PAMPs, form the basis of 
adjuvants. Adjuvants potentiate immune responses, reducing the dosing requirements 
needed to induce protective immunity, particularly for weakly immunogenic subunit 
vaccines. Few adjuvants are licensed for human use: principally alum, and squalene-
based oil-in-water adjuvants. Yet there are many types of potential adjuvant, including 
proteins, oligonucleotides, drug-like small-molecules, and liposome-based delivery 
systems.  
So-called Small Molecule Adjuvants (SMAs) are the most underexplored of existing 
adjuvants, despite the observation that many small molecules exhibit overt 
adjuvanticity. SMAs include both complex biologically-derived natural products and 
fully-synthetic drug-like molecules [26]. Notable natural Product SMAs include QS21; 
muramyl dipeptide; various formulations of mannide monooleate, MurNAc-L-Ala-γ-D-
Glu-mDAP (M-TriDAP), and Monophosphoryl-Lipid A (or MPL).  
Fully-synthetic drug-like small molecules are also adjuvants [26]: for example, 
Bestatin (Ubenimex or UBX), Levamisole; Bupivacaine; and 2-(4-Methoxyphenyl)-N-
methylethanamine also known as compound 48/80. Yet easily the best explored of 
SMAs are the so-called Imidazoquinolines, the best known are Imiquimod, 
Resiquimod, and Gardiquimod, these target Toll-like receptors: TLR7 and/or TLR8, 
inducing IFN, TNF and IL-12 secretion.  
SMAs can also be discovered systematically using virtual screening approaches 
[26]: the best example is our discovery of adjuvants functioning as antagonists of the 
CCR4 Chemokine receptor. Inhibiting CCR4 receptors may give rise to adjuvantism as 
the receptor is expressed by regulatory T-cells (or Tregs) that normally suppress 
immune responses [27]. Inhibiting CCR4 function is anticipated to exacerbate vaccine 
responses.  By combining experimental validation with virtual screening, we have 
identified several potential adjuvants, acting through the apparent inhibition of Treg 
proliferation [28][29]. Three-dimensional or structure-based virtual screening (SB-VS), 
which utilises automated protein docking (APD), is an effective means of identifying 
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ligands with great celerity [30][31][32]. VS can identify real, high-affinity ligands with 
unmatched cost-effectiveness and efficiency. APD-based SB-VS can dock 
innumerable ligand molecules into a defined binding site [33]. SB-VS is exceptionally 
logistically efficient, saving time, labour, and resource. Months of robotically-mediated 
experimentation are replaced by weeks of computational analysis, complemented by a 
handful of reliable, hand-crafted assays. At most a few hundred molecules need be 
tested [33]. This handful is put through a hierarchical cascade of highly specific and 
informative assays in vitro, with actives then tested for their whole system adjuvant 
properties in vivo. The molecules we found [28][29] behave appropriately in a variety of 
in vitro assays, and increase the levels of various correlates of protection in vaccinated 
mice, and even show some enhancement in related challenge models observations 
supported by independent analysis [34]; and also shows activity against potential 
cancer antigens [35].  
Higher order systems 
Much of what we have discussed above has focussed on the analysis of 
experimental structures and sequences. Although 3D modelling of epitope MHC and 
epitope-antibody interactions have occasionally been illuminating, other uses of explicit 
3D modelling of immune receptors has been more edifying and successful.   
A key example is provided by the trimeric MHC-peptide-TCR (pMHC-TCR) complex, 
a supramolecular complex at the heart of the cellular immune response [36]. Small 
molecule drugs can block allele specific peptide presentation to T-cells, which is both a 
potential mechanism to exploit therapeutically [37][38] and a pathological mechanism 
leading to so-called Adverse Drug Actions [39][40]. For many Adverse Drug Reactions 
(ADRs), particularly cutaneous ADRs, there is a strong association between the 
reaction to certain drugs (including abacavir, allopurinol, carbamazepine, and other 
antiepileptic drugs) and particular HLA alleles, allowing for the prognostic prediction of 
ADRs. There is likewise a potential relationship between the haplotype of donor and 
recipient and the outcomes of stem-cell and solid organ transplants.  
Establishing relationships for these rare events is complicated by the 3000+ different 
MHC alleles known to exist in the global human population, which in its turn leads to 
the extraordinary potential for distinct peptide specificities within the global patient 
population. Each MHC allele has a unique sequence, and thus unique 3-dimensional 
structure and functional properties, including their binding specificity for peptides and 
TCRs; and it is possible to compare MHC structure as a way to classify them in terms 
 7 
of such important functional interactions. We have recently used poisson-boltzmann 
electrostatic potential as a meaningful arbiter of through-space molecular interactions 
combined with sophisticated data-mining methods to address this. By rigorous state-of-
the-art analysis of projected properties, we identified clusters corresponding to the 
three class I human MHC loci, and sub groups therein. It is notable that this recovers 
the HLA-A; HLA-B, and HLA-C alleles without any prior knowledge of such a division. 
This gives confidence to any assertion we might make regarding the other division of 
the allele population into structurally and functionally similar sub-groups. Supertype 
analysis has potential applications in the classification of MHC specificity for peptide 
and TCR interaction, with implications therefore for epitope prediction, solid organ and 
bone marrow transplantation, mate-choice, and MHC-mediated adverse drug 
reactions.    
Molecular dynamic simulations have long been applied to attempting to unravel the 
many mysteries of the immune system [41]. Powered by the availability of 
supercomputing MD simulations can now tackle very large systems [42]. Yet even the 
largest immunological simulation is small compared to such biomolecular simulations. 
Assisted by rapid advances in experimental imaging and quantitative proteomics, 
simulations begin to approach the mesoscale [43]; and we can look to simulate in a 
reasonably realistic way biologically meaningful cellular events. For example, we have 
simulated at atomic resolution a detailed molecular model of part of the immune 
synapse, comprising CD4, peptide-MHC, TCR, and membrane regions [42]. MD will 
ultimately break free from the many restrictions imposed by the limited data we 
currently have, allowing us the luxury of de novo prediction of equilibrium binding and 
kinetic constants. Beyond that, we can envisage conducting simulations that pose 
biological questions that can only be answered by experiment, which in turn will drive 
the design of experiments. 
Agent based models in computational vaccinology 
Computational models are important for the understanding of biological systems. 
Such models can be applied to enhance or predict therapeutic effects at the organism 
level. The pharmaceutical companies suggest that computational biology can play an 
excellent role in this field [44]. In silico models can afford answers to the general 
behaviour of the immune system, the analysis of cellular and molecular interactions, 
the effects of treatments, and the course of diseases. 
The use of agent based modelling (ABM) is suitable both to perform in silico 
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experiments which lead to formulate and/or validate biological hypotheses and to give 
useful hints for the design of optimal treatment schedules. Moreover, ABM approach 
can be used at cellular level to describe complex systems in a flexible way, including 
the handling of entity heterogeneity and physical space. ABMs aim at recreate and 
predict the cellular interactions simulating the behaviour and the interactions of 
autonomous entities (cells and molecules). The dynamic agents can be described as a 
function of time, a position, and an internal state that includes most important 
properties of the agent, such as age.  
One of the successful applications of ABM in computational vaccinology is 
represented by SimTriplex [1], a specialized cellular automaton able to model 
mammary carcinoma, Triplex vaccine and the immune system competition. Triplex is 
an immunopreventive HER-2/neu breast cancer vaccine [2], which combines the 
specific target antigen, p185(HER-2/neu) with two non-antigen specific adjuvants: IL-12 
and allogeneic major histocompatibility complex (MHC) class I molecules. Four vaccine 
administration schedules (early, late, very late and chronic) have been tested on HER-
2/neu transgenic mice, and the chronic schedule showed that it is the only one that 
provides complete, long- term protection from mammary carcinoma. 
SimTriplex mimics the behaviour of immune cells at the cellular level in both 
vaccinated and in naive mice. The simulator incorporates a variety of cellular and 
molecular entities, including tumour and vaccine cells. Modifications of state (e.g., cell 
activation, cytotoxicity, cell death, etc.) are ruled by a set of policies based on tumour 
immunology. The model coupled with optimization techniques (based on combinatorial 
optimization algorithms as genetic algorithms and simulated annealing [7][8]) allowed 
to search for an optimal vaccination schedule to obtain the same efficacy of the chronic 
protocol with a definitively reduced vaccine administrations. SimTriplex predictions 
have been verified in a in-vivo experiment. Outcomes show that in-silico predicted 
schedule does significantly reduce the tumours multiplicity on the ten mice mammary 
glands even if the vaccination efficacy for the first appearing of tumour was still 
overestimated. Further adjustment of the model is required to include evidence of 
immune aging which appeared from in vivo follow up results [3][4]. 
The Triplex vaccine proved to be effective also as a therapeutic vaccine, showing its 
ability to be used against induced lung metastases [5]. A major goal of biologists is to 
better understand the biological behaviour to improve the efficacy of the therapeutic 
treatment and to try to predict, for example, the outcomes of longer experiments in 
order to move faster towards clinical phase I trials. In a recent work [6], the authors 
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present MetastaSim, an ABM to be used as an in silico virtual lab with the target to 
help answering these questions. MetastaSim has the ability to simulate the cancer 
growth kinetics and multiple different metastatic nodules, each one with its own growth 
rate, in an accurate way. To reproduce the growth in time of nodules, the Gompertz 
growth law is used in its differential form. Simulations results showed that it is possible 
to obtain in silico a reduction of approximately 45% in the number of vaccinations. Most 
of the protocols presented there share a similar vaccination strategy that is composed 
by a boost of three vaccine injections, a period of rest, and then a series of vaccine 
recalls that are somewhat equally spaced. The model suggests that any optimal 
protocol for preventing lung metastases formation should be therefore composed by an 
initial massive vaccine dosage followed by few vaccine recalls. Even if this is a well-
known vaccination strategy in immunology, since it is commonly used for many 
infectious diseases such as tetanus and hepatitisB, it can be still considered a relevant 
result in the field of cancer-vaccines immunotherapy. 
Vaccination strategies can be also used as therapeutics solutions. Immunological 
therapy of progressive tumours, in particular, requires both the activation and 
expansion of tumour specific cytotoxic T lymphocytes, and an efficient migration of 
these effector cells in the tumour tissue.  
In order to investigate in silico the melanoma progression and the effects of a 
therapeutic vaccination strategy against such tumour, an ABM named SimB16 has 
been realized and presented in [45].  
SimB16 has been initially validated using in vivo results, and then used to predict the 
critical role of CD137 expression on tumour vessel endothelium. Thus it allowed to 
analyse the effects of anti-CD137 mAb derived by adoptive transfer of activated OT-1 T 
cells in B16-OVA mice. 
Predictions show that early infiltration of T cells seems to be dependent on CD137 
expression on tumor vasculature, an this represents an important factor that must be 
taken into account in order to understand in vivo results and to design future 
administration strategies. 
In [46] Kim and Lee present a hybrid ABM-delay differential equation (DDE) 
model to reproduce the general behaviour of preventative cancer vaccines (particularly 
cytotoxic T lymphocytes (CTLs)) in order to obtain Anti-Tumour Immunity. The model 
does not tackle a specific in vivo problem, but tries to theoretically understand the 
feasibility of CTL based vaccines. According to the model, an anti-cancer memory CTL 
pool of approximately 3% can successfully eradicate a tumour population under a wide 
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range of biological hypotheses and scenarios, implying that a vaccination approach is 
feasible. Moreover, the model reveals some conditions that may entitle rapid tumour 
destruction, oscillation, and polynomial rather than exponential decline in the tumour 
population. 
Another ABM-based approach to simulate vaccination in cancer immunotherapy 
is given by the VaccImm Server [47]. This online model represents the first tool that 
tries to enable the simulation at a cellular scale of peptide vaccination using real amino 
acid sequences to reproduce molecular binding sites. Simulations can be executed 
directly online, and results allow to analyse the parameter space of the involved entities 
and to reveal the complex and patient-specific nature of peptidic vaccination in cancer 
immunotherapy.  It must be said that VaccImm uses classical molecular prediction 
tools in order to determine the affinity between receptors, so its results highly depend 
on the accuracy of such molecular tools. 
 
Mathematical models in computational vaccinology 
Mathematical models have been used since many years to represent various 
aspects of immune system and related pathologies, however their application to 
describe the effects of vaccines has been quite limited.  
 These models are mainly based on differential equations (ordinary, partial, 
delay, and/or stochastic) and are applied to describe the dynamics of immune system 
entities, cells, pathogens and treatments from a population point of view, rather than 
follow such entities individually, as seen in ABMs. 
They are built on a strong and solid mathematic theory, and for simple models 
(i.e. with a limited number of simple equations) it is possible to find an analytical 
solution. However, for more complex models, the use of computational techniques that 
are focused in finding an approximate solution is mandatory. 
The trade-off between tractability (and solvability) versus biological coherence 
usually tends on the former, thus such models are usually less accurate in describing 
the immunological background than ABMs. However their application to some specific 
problems allows to extract some fundamental properties, to study the parameter’s 
space, and to provide sensitivity analysis. For example, the same problems tackled by 
SimTriplex and SimB16 ABMs have been explored from a qualitative point of view by 
ordinary and delay differential equation (ODE and DDE) based models [48][49][50]. 
In [51] Davis et al. present a mathematical model based on DDE to model shigella 
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immune dynamics. The model does not care into account a specific vaccine, but it is 
used to determine which immune system responses must be stimulated by any 
candidate vaccine. According to the model, antibody-based vaccines targeting only 
surface antigens cannot elicit sufficient immunity for protection. However, boosting anti-
lipopolisaccaride (LPS) B memory cells can help and give protection against shigella. 
Furthermore an extension of the model reveals that targeting both LPS and epithelial 
entry proteins could represent a favourable approach in designing new vaccines.  
Differential equation based models have been mainly applied to cancer 
vaccinology. Papalardo et al. [52] developed an ordinary differential equation (ODE) 
based model to evaluate the number and the frequency of vaccine boosts needed to 
obtain a long-lasting and protecting memory T-cell response.  The model includes both 
activated cytotoxic T lymphocytes and memory T cells, and is used to investigate the 
induction of immunological memory in wild-type mice injected with a dendritic cell-
based vaccine, both in the presence and in the absence of memory T cells. A good 
agreement between ex vivo and in silico experiments underlines how the model is able 
to reproduce the expansion and persistence of antigen-specific memory T cells. 
Moreover statistical sensitivity analysis allowed the identification of a time window in 
which boosts may be detrimental. 
 Parra-Guillen et al. [53] use an approach based on an incremental series of 
steps to develop a mathematical model which describes the tumour response in mice 
after vaccination. The authors investigate its applicability to study cytokine-based 
strategies that can modulate the immune system response. In order to successfully 
describe the different outcomes obtained after vaccine administration different models 
have been integrated and used: (1) A Model of tumour growth in mice without 
treatment using a linear model; (2) A Model of the vaccine effects assuming that the 
vaccine triggers a delayed immune response that leads to cancer cells death (using 
two compartments); (3) A Model to reproduce a resistance effect that decreases the 
vaccine efficiency based on the size of tumour; (4) a mixture model to represent the 
relapse of the tumour, an event that has been observed in a small percentage of 
animals. 
A mathematical model based on ODE has been developed by Wilson and Levy in 
order to gain insights about the combined effects of anti-TGF-β treatments and 
vaccines against tumours. The mathematical model takes into account the dynamics of 
the tumour growth, the concentration of TGF-β, the action of activated cytotoxic 
effector and regulatory T cells.  No treatment, anti-TGF-β treatment, vaccine treatment, 
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and combined anti-TGF-β vaccine treatments scenarios are investigated through 
numerical simulations and stability analysis. The model well reproduces the observed 
experimental results, and could be in principle used to help the design of new 
treatments that include TGF-β. 
Another example of the application of mathematical models to cancer 
vaccinology is represented by the work by Joshi et al. [55].  The authors present 
mathematical model based on ODE of therapeutic vaccination against cancer, and 
focus on the role of antigen presentation and co-stimulatory signalling pathways. The 
effects of different vaccination protocols on the well-documented phenomena of cancer 
dormancy and recurrence have been studied by means of numerical simulations. 
Results suggest a possible explanation of why adoptive immunotherapies can indeed 
sometimes promote tumour growth. Moreover simulations suggest that an elevated 
number of professional APCs well correlate with prolonged time periods of cancer 
dormancy. 
Conclusions 
Complexity is the hall mark of many somatic systems; not least the Immune system. 
Computational approaches are finally beginning to shine an illuminating light on how 
the Immune System functions at many levels, peeling away the obfuscating layers that 
have hitherto obscured our understanding. The functioning and mis-functioning of the 
Immune system lies at the heart of defence against infection and cancer and the 
induction of autoimmune disorders respectively. The ability to interact with the immune 
system through vaccination has created the most efficacious and efficient intervention 
in medical history, saving uncountable millions of lives across hundreds of years. The 
proven ability of computation to design vaccines and adjuvants, and to optimize 
vaccination protocols is beginning to open up a new era of computational vaccinology 
that will in time bring in its wake untold benefits to the burgeoning global population 
both through human vaccination but also in combating climate change and protecting 
livestock and aquaculture.   
At the molecular level, the potent combination of data-driven machine learning 
methods and Molecular Dynamics-based atomistic simulation have allowed the 
development of various approaches that address a variety of key applications. Some 
have proved successful, including T cell-mediated epitope prediction for well-studied 
alleles, while others have yet to deliver on their true potential, such as the prediction of 
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antibody-mediated B-cell epitope prediction, which currently is often more misleading 
than helpful. One of the most promising approaches is the use of large scale dynamics 
simulations of cellular systems that can explore the behaviour of complex systems that 
currently lie beyond the power of experimental biophysics to properly evaluate. While 
we are at least several decades away from simulating a whole eukaryotic cell, it is now 
possible to simulate supramolecular systems of hitherto inconceivable size and 
complexity using multi-scale approaches that combine both atomistic and various 
levels of course-grained simulations.   
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Figure 1 – Graphical abstract. The functioning and mis-functioning of the Immune 
system lies at the heart of defence against infection and cancer and the induction of 
autoimmune disorders respectively. Nowadays, traditional methodologies in vaccine 
research are combined with computational vaccinology i.e., computational strategies 
to design vaccines and adjuvants, and to optimize vaccination protocols. These 
methodologies act at different levels and one the most ambitious goal is to have 
them integrated together to reach a multiscale view and approach.  
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